AnaptysBio stock hits 52-week high at 43.35 USD By Investing.com
AnaptysBio stock hits 52-week high at 43.35 USD…
45,690$
0,07%
Echtzeit-Aktienkurs Anaptysbio Inc.
Bid:
Ask:
Nachrichten zur Anaptysbio Inc. Aktie
Anaptys Announces Participation in December Investor Conferences
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
GSK unit sues AnaptysBio in row over Jemperli rights
GSK PLC (LSE:GSK, NYSE:GSK) has stepped up a dispute over rights to its fast-growing cancer drug Jemperli by having its US…
AnaptysBio, Inc. (ANAB) Surpasses Q3 Earnings and Revenue Estimates
AnaptysBio (ANAB) delivered earnings and revenue surprises of +149.06% and +145.36%, respectively, for the quarter ended September 2025. Do the…
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
AnaptysBio, Inc. (ANAB) Discusses On Strategic Separation To Maximize Shareholder Value (Transcript)
…
AnaptysBio: Rosnilimabs RA Data Sets The Stage For Blockbuster Potential
…
AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement
…
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates
AnaptysBio (ANAB) delivered earnings and revenue surprises of 1.54% and 52.31%, respectively, for the quarter ended March 2025. Do the…
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last?
AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might…
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates
AnaptysBio (ANAB) delivered earnings and revenue surprises of 55.28% and 324.09%, respectively, for the quarter ended December 2024. Do the…
Anaptys Announces Participation in March Investor Conferences
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?
AnaptysBio (ANAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend…
AnaptysBio stock soars on positive RA trial results By Investing.com
AnaptysBio stock soars on positive RA trial results…
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
Ecor1 Capitals Oleg Nodelman acquires $1.1m in AnaptysBio stock By Investing.com
Ecor1 Capitals Oleg Nodelman acquires $1.1m in AnaptysBio stock…
AnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis Readout
…
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching
…
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
Anaptys Announces Participation in November and December Investor Conferences
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
AnaptysBio: Too Risky, Especially After GSK Drops Its Related Programs
…
Why AnaptysBio Was Such a Healthy Stock This Week
The companys immediate future looks promising, as it has a drug that should get a clinical readout within months and…
AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point
…
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
AnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade)
…
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?
AnaptysBio (ANAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate…
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
A powerfully bullish new analyst take on the company helped it rally on the market.…
Wedbush raises AnaptysBio to outperform, cites upcoming data
…
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…